Denali Therapeutics Inc.
161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 866 8548
https://www.denalitherapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 375
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director | 1.15M | 3.65M | 1976 |
| Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Secretary | 802.29k | 1.65M | 1973 |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder & Independent Director | 57.5k | 無 | 1960 |
| Dr. Carole Ho M.D. | Chief Medical Officer & Head of Development | 802.29k | 無 | 1973 |
| Mr. Tyler M. Nielsen | Senior Vice President of Corporate Finance | 無 | 無 | 1978 |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | 無 | 無 | 無 |
| Mr. Joe Lewcock Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
| Dr. Laura Hansen | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Chris Walsh | General Counsel | 無 | 無 | 無 |
| Mr. Mark Rowen | Vice President of Corporate Development | 無 | 無 | 無 |
描述
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
公司管治
截至 2024年6月1日 止，Denali Therapeutics Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：2；董事會：4；股東權利：8；現金賠償：8。
